Heparin-Binding EGF-Like Growth Factor human
SIGMA/E4643 - HB-EGF, recombinant, expressed in baculovirus infected Sf21 cells, lyophilized powder, suitable for cell culture
Synonym: hHB-EGF; HB-EGF; Heparin-Binding Epidermal Growth Factor-Like Growth Factor
MDL Number: MFCD00212935
Product Type: Chemical
| assay | ≥97% (SDS-PAGE and N-terminal analysis) |
| biological source | human |
| form | lyophilized powder |
| mol wt | 9.5 kDa |
| packaging | pkg of 50 and 250 μg |
| potency | ≤3 ng/mL |
| quality | endotoxin tested |
| Quality Level | 100 ![]() |
| recombinant | expressed in baculovirus infected Sf21 cells |
| storage condition | avoid repeated freeze/thaw cycles |
| storage temp. | −20°C |
| technique(s) | cell culture | mammalian: suitable |
| UniProt accession no. | Q99075 ![]() |
| Analysis Note: | The biological activity is measured by its ability to stimulate 3H-thymidine incorporation in the EGF-responsive BALB/3T3 cells. |
| Biochem/physiol Actions: | Heparin-binding epidermal growth factor (HB-EGF), like BTC, is a heparin-binding EGF family member. Natural soluble HB-EGF is a 19 kDa glycoprotein of multiple forms due to heterogeneous truncations. Soluble HB-EGF is mitogenic and chemotactic for fibroblasts, keratinocytes, and smooth muscle cells but not capillary endothelial cells. Production of HB-EGF is detected in monocytes, macrophages, and vascular and aortic smooth muscle cells (SMC). HB-EGF may play a role in the pathogenesis of atherosclerosis. It may also be an effector of Jun-induced oncogenic transformation. HB-EGF binds to EGFR with high affinity and to ErbB with moderate affinity. |
| Physical form: | Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing 2.5 mg bovine serum albumin. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥97% (SDS-PAGE and N-terminal analysis) |
| Storage Temp. | −20°C |
| UNSPSC | 12352202 |

